$6.36 $0.27 (4.4%)

03:23 PM EST on 11/20/19

GlycoMemetics (NASDAQ:GLYC)

CAPS Rating: 2 out of 5

Current Price $6.36 Mkt Cap $264.1M
Open $6.04 P/E Ratio 0.00
Prev. Close $6.09 Div. (Yield) $0.00 (0.0%)
Daily Range $6.04 - $6.39 Volume 172,680
52-Wk Range $2.64 - $13.56 Avg. Daily Vol. 212,722

Caps

How do you think NASDAQ:GLYC will perform against the market?

Add Stock to CAPS Watchlist

All Players

38 Outperform
3 Underperform
 

All-Star Players

13 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:GLYC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Andyman (84.05)
Submitted April 03, 2014

Love the science, management, and original investors.The two guys who originally designed the selectin inhibitors on which GLYC's drug candidates are based both still work for the company. The inhibitors will allow the company can develop and license… More

zzlangerhans (99.78)
Submitted March 31, 2015

I have a fairly straightforward problem with GlycoMimetics, which is that I think that their lead candidate rivipansel is dead and the share price has not declined to take this into account. Pfizer not initiated a phase III trial of rivipansel… More

NASDAQ:GLYC VS S&P 500 (SPY)

NASDAQ:GLYC Summary

Recent Community Commentary

Read the most recent pitches from players about GLYC.

Recs

0
Member Avatar TMFEBCapital (84.61) Submitted: 12/18/2017 3:28:42 PM : Outperform Start Price: $16.37 NASDAQ:GLYC Score: -77.26

Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.

Recs

0
Member Avatar manirg (< 20) Submitted: 12/2/2014 8:41:39 AM : Outperform Start Price: $8.45 NASDAQ:GLYC Score: -75.93

Undervalued

Recs

2
Member Avatar Andyman (84.05) Submitted: 4/2/2014 10:12:16 PM : Outperform Start Price: $16.64 NASDAQ:GLYC Score: -126.32

Love the science, management, and original investors.

The two guys who originally designed the selectin inhibitors on which GLYC's drug candidates are based both still work for the company. The inhibitors will allow the company can develop and license a whole family of drugs based on the same technology that treat diseases in which inflammation plays a crucial role. That's a huge pool of potential disease targets, and a huge pool of potential revenue.

The CEO was very smart to select a first target (vaso-occlusive crisis of sickle cell disease) that permitted the company fast-track AND orphan drug status with the FDA. That means a much shorter time-to-market. They could have gone with a disease that afflicts a bigger patient population, but they were able to get proof of concept for this new class of molecule much more quickly (and far less expensively) this way.

Their partnership with Pfizer when they were still just a tiny startup speaks volumes about the potential for this company. I'm in with real money.

Leaderboard

Find the members with the highest scoring picks in GLYC.

Score Leader

drugtrader

drugtrader (86.75) Score: +305.74

The Score Leader is the player with the highest score across all their picks in GLYC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Under5 < 20 8/16/2019 Outperform 5Y $2.91 +116.84% +8.34% +108.50 0 Comment
Playa14 < 20 9/4/2019 Outperform 5Y $3.33 +89.49% +5.94% +83.55 0 Comment
WildShaman 97.09 7/9/2018 Underperform 5Y $16.93 -62.73% +12.30% +75.03 0 Comment
ababrmon 72.29 5/18/2017 Underperform 5Y $11.10 -43.42% +31.29% +74.72 0 Comment
giftofgod 93.83 8/13/2018 Underperform 1Y $14.46 -56.36% +9.55% +65.92 0 Comment
mrmrmrj 53.20 11/18/2019 Outperform 5Y $5.69 +10.99% -0.50% +11.49 0 Comment
mctracker1 47.01 3/7/2016 Outperform NS $5.25 +19.62% +55.69% -36.07 0 Comment
dundara 94.68 9/6/2016 Outperform 1Y $7.22 -13.02% +41.91% -54.93 0 Comment
drugtrader 86.75 9/18/2018 Outperform 5Y $13.97 -54.83% +7.24% -62.08 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. zzlangerhans 99.78 10/23/2017 Outperform 1Y $11.13 -43.58% +20.53% -64.11 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GLYC.